Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.67 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073739 | 1.00 | BACE1 (0.67) | BACE1BACE2CTSD | |
| SCHEMBL6524838 | 1.00 | BACE1 (0.67) | BACE1BACE2CTSD | |
| SCHEMBL20271298 | 0.86 | BACE1 (0.64) | BACE1BACE2CTSD | |
| SCHEMBL20271294 | 0.86 | BACE1 (0.64) | BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL3189361 | 0.85 | BACE1 (0.62) | BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL3189347 | 0.85 | BACE1 (0.62) | BACE1BACE2CTSD | |
| SCHEMBL14980702 | 0.84 | BACE1 (0.66) | BACE1BACE2 | |
| SCHEMBL15451125 | 0.84 | BACE1 (0.66) | BACE1BACE2 | |
| SCHEMBL4074340 | 0.82 | BACE1 (0.58) | BACE1BACE2CTSD | |
| SCHEMBL6517999 | 0.82 | BACE1 (0.65) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475658-A1 | 2 -AMINODIHYDRO [1, 3]THIAZINES AS BACE 2 INHIBITORS FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8884062-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8884062-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8168630-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8168630-B2 | Aminodihydrothiazine derivatives substituted with a cyclic group | SHIONOGI & CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-2151435-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALZHEIMER'S DISEASE | Shionogi&Co., Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | BACE1 14/4885BACE2 124/4885CTSD 3129/4885 |
| US-20140221360-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | BACE1 2843/4885BACE2 1846/4885CTSD 3820/4885 |
| US-20120172355-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | BACE1 6/4885BACE2 14/4885CTSD 955/4885 |
| US-20110065695-A1 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES | SLC5A2, SLC5A1, GLP1R | BACE1 2843/4885BACE2 1846/4885CTSD 3820/4885 |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | BACE1 17/4885BACE2 135/4885CTSD 3165/4885 |
| US-20100075957-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | BACE1 5/4885BACE2 14/4885CTSD 1322/4885 |
| US-20140073815-A1 | AMINODIHYDROTHIAZINE DERIVATIVES SUBSTITUTED WITH A CYCLIC GROUP | APP, IAPP, APBA1 | BACE1 6/4885BACE2 14/4885CTSD 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.